Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

(2017) Mark S Freedman et al.   Multiple Sclerosis Journal

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

(2017) Mark S Freedman et al.   Multiple Sclerosis Journal

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study

(2017) Patricia K. Coyle et al.   Multiple Sclerosis and Related Disorders

Secondary Progressive Multiple Sclerosis: Definition and Measurement

(2016) Domenico Plantone et al.   CNS DRUGS

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

(2016) Patrick Vermersch et al.   Multiple Sclerosis Journal

Estimating a treatment effect: Choosing between relative and absolute measures

(2016) Maria Pia Sormani et al.   Multiple Sclerosis Journal

Long-term safety and efficacy of teriflunomide

(2016) Paul O'Connor et al.   NEUROLOGY

Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

(2016) Aziz Filali-Ansary et al.   THERAPEUTIC DRUG MONITORING

Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

(2016) Robert Zivadinov et al.   Expert Review of Neurotherapeutics

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

(2016) Patrick Vermersch et al.   Multiple Sclerosis Journal

Estimating a treatment effect: Choosing between relative and absolute measures

(2016) Maria Pia Sormani et al.   Multiple Sclerosis Journal

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis

(2016) Mark S. Freedman et al.   Multiple Sclerosis and Related Disorders

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

(2016) Giancarlo Comi et al.   Multiple Sclerosis and Related Disorders

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

(2016) Bhupendra O. Khatri   Therapeutic Advances in Neurological Disorders

Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial

(2015) L. Kappos et al.   NEUROLOGY

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

(2014) Amit Bar-Or et al.   DRUGS

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

(2014) P. Browne et al.   NEUROLOGY

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

ECTRIMS 2013: Posters I

(2013)   Multiple Sclerosis Journal

Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

(2013) A. Bar-Or et al.   NEUROLOGY

Scoring treatment response in patients with relapsing multiple sclerosis

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison

(2008) Mark S. Freedman et al.   EUROPEAN NEUROLOGY